
  
    
      
        Introduction_NNP
        Antecedent_NNP infection_NN with_IN many_JJ different_JJ microbes_NNS is_VBZ
        often_RB associated_VBN with_IN the_DT development_NN of_IN autoimmune_JJ disease_NN
        in_IN humans_NNS ,_, but_CC the_DT pathogenic_JJ mechanisms_NNS involved_VBN ,_, if_IN any_DT ,_,
        are_VBP unknown_JJ ._. Most_JJS of_IN the_DT microbes_NNS associated_VBN with_IN
        autoimmune_JJ disease_NN have_VBP been_VBN viruses_NNS ,_, particularly_RB
        cytomegalovirus_JJ (_( CMV_NNP )_) ,_, Epstein-_NNP Barr_NNP virus_NN ,_, and_CC
        varicella-zoster_JJ virus_NN ._. CMV_NNP has_VBZ been_VBN associated_VBN with_IN the_DT
        increased_VBN production_NN of_IN rheumatoid_NN factor_NN ,_, antiphospholipid_NN
        antibodies_NNS ,_, cold_JJ agglutinins_NNS ,_, antimyosin_NN antibodies_NNS ,_,
        anti-endothelial_JJ cell_NN antibodies_NNS ,_, and_CC antiganglioside_NN
        antibodies_NNS ._. One_CD study_NN found_VBD an_DT increased_VBN incidence_NN of_IN
        anti-_NN CMV_NNP antibodies_NNS among_IN patients_NNS with_IN systemic_JJ lupus_JJ
        erythematosus_JJ [_NN 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD ]_NN ._.
        Neutralizing_NNP antibodies_NNS induced_VBN by_IN CMV_NNP are_VBP directed_VBN
        primarily_RB against_IN the_DT major_JJ envelope_NN protein_NN of_IN CMV_NNP ,_,
        glycoprotein_NN B_NNP (_( gB_NN )_) ._. Antibodies_NNP to_TO CMV_NNP gB_NN share_NN some_DT
        homology_NN with_IN rheumatoid_NN factor_NN ,_, thus_RB providing_VBG a_DT
        theoretical_JJ relationship_NN between_IN CMV_NNP infection_NN and_CC
        autoimmune_JJ disease_NN [_NN 12_CD ]_NN ._. An_DT adenovirus-_NN CMV_NNP gB_NN construct_VB
        vaccine_NN administered_VBN to_TO mice_NNS induced_VBD a_DT statistically_RB
        significant_JJ increase_NN in_IN the_DT production_NN of_IN antibodies_NNS to_TO
        U_NNP 1_CD -_: 70_CD kD_NN antibody_NN in_IN both_DT normal_JJ and_CC autoimmune-prone_JJ mice_NNS
        [_NN 13_CD ]_NN ._. Newkirk_NNP 
        et_CC al_NN ._. recently_RB reported_VBD an_DT
        increased_VBN incidence_NN of_IN antibodies_NNS to_TO Sm_NNP antigen_NN and_CC
        antibodies_NNS to_TO ribonucleoprotein_NN (_( RNP_NNP )_) among_IN naturally_RB
        CMV-infected_NNP individuals_NNS ,_, as_RB well_RB as_IN an_DT increase_NN in_IN
        antibodies_NNS to_TO U_NNP 1_CD -_: 70_CD kD_NN [_NN 14_CD ]_NN ._.
        To_TO confirm_VB the_DT findings_NNS of_IN Newkirk_NNP 
        et_CC al_NN ._. [_NN 14_CD ]_NN ,_, we_PRP evaluated_VBD sera_NN
        from_IN individuals_NNS either_DT naturally_RB infected_VBN with_IN CMV_NNP or_CC
        immunized_JJ with_IN the_DT live_JJ attenuated_JJ Towne_NNP strain_NN of_IN CMV_NNP for_IN
        the_DT presence_NN of_IN antibodies_NNS to_TO three_CD antigens_NNS :_: Sm_NNP ,_, RNP_NNP ,_, and_CC
        U_NNP 1_CD -_: 70_CD kD_NN ._. We_PRP also_RB assessed_VBD the_DT correlation_NN between_IN
        production_NN of_IN antibodies_NNS to_TO gB_NN and_CC antibodies_NNS to_TO Sm_NNP or_CC
        RNP_NNP ._.
      
      
        Methods_NNP
        
          Subjects_NNP
          Anonymously_NNP coded_VBN serum_NN specimens_NNS had_VBD been_VBN stored_VBN at_IN
          -_: 80_CD °_NN C_NNP ._. These_DT were_VBD preimmunization_NN screening_NN sera_NN from_IN 80_CD
          normal_JJ healthy_JJ adult_NN females_NNS who_WP volunteered_VBD for_IN a_DT Towne_NNP
          vaccine_NN study_NN ._. Forty_CD naturally_RB seropositive_JJ and_CC 40_CD
          seronegative_JJ sera_NN were_VBD used_VBN ._. Subjects_NNP were_VBD aged_VBN between_IN
          20_CD and_CC 53_CD years_NNS (_( the_DT ages_NNS of_IN four_CD individuals_NNS were_VBD not_RB
          recorded_VBN )_) ._. Also_RB included_VBD were_VBD postimmunization_NN serial_NN
          sera_NN from_IN eight_CD normal_JJ healthy_JJ women_NNS who_WP had_VBD received_VBN
          6000_CD plaque_NN forming_VBG units_NNS of_IN the_DT live_JJ attenuated_JJ Towne_NNP
          vaccine_NN as_IN a_DT single_JJ subcutaneous_JJ injection_NN ._. Following_VBG
          immunization_NN ,_, all_DT eight_CD subjects_NNS developed_VBD antibodies_NNS to_TO
          CMV_NNP and_CC to_TO CMV_NNP gB_NN ._. Seventy-five_NNP per_IN cent_NN of_IN the_DT CMV_NNP
          seropositive_JJ subjects_NNS and_CC 85_CD %_NN of_IN the_DT CMV_NNP seronegative_JJ
          subjects_NNS were_VBD Caucasian_NNP ;_: the_DT remainder_NN were_VBD
          Afro-_NNP American_NNP ._.
        
        
          Screening_NNP for_IN anti-_NN CMV_NNP antibodies_NNS
          Sera_NNP were_VBD tested_VBN for_IN the_DT presence_NN or_CC absence_NN of_IN IgG_NNP
          antibodies_NNS to_TO CMV_NNP by_IN either_DT latex_NN agglutination_NN (_( CMVScan_NNP ;_:
          Becton_NNP Dickinson_NNP ,_, Sparks_VBZ ,_, MD_NNP ,_, USA_NNP )_) or_CC by_IN enzyme_NN
          immunoassay_NN (_( EIA_NNP )_) as_RB previously_RB described_VBD [_NN 15_CD ]_NN ._.
        
        
          Detection_NNP of_IN antibodies_NNS against_IN Sm_NNP and_CC RNP_NNP
          An_DT indirect_JJ ,_, noncompetitive_JJ EIA_NNP was_VBD used_VBN for_IN both_DT Sm_NNP
          and_CC RNP_NNP antigens_NNS to_TO detect_VB IgG_NNP antibodies_NNS ._. Microplate_NNP
          wells_NNS coated_VBN with_IN antigen_NN bound_VBN human_JJ antibody_NN ,_, which_WDT was_VBD
          subsequently_RB bound_VBN by_IN an_DT enzyme-labeled_JJ conjugate_NN
          antibody_NN and_CC quantitated_JJ colorimetrically_RB (_( Varelisa_NNP ;_:
          Pharmacia_NNP &_CC Upjohn_NNP ,_, Freiburg_NNP ,_, Germany_NNP )_) ._. Sera_NNP were_VBD
          diluted_VBN 1_CD :_: 101_CD for_IN both_DT assays_NNS ._.
          The_DT Sm_NNP antigen_NN used_VBN in_IN this_DT assay_NN was_VBD purified_JJ from_IN
          calf_NN thymus_JJ ._. The_DT human_JJ recombinant_JJ RNP_NNP antigens_NNS used_VBN
          included_VBD the_DT U_NNP 1_CD -_: 70_CD k_NN ,_, U_NNP 1_CD A_DT ,_, and_CC U_NNP 1_CD C_NNP antigens_NNS ._. For_IN both_DT Sm_NNP
          and_CC RNP_NNP ,_, specific_JJ quantitative_JJ values_NNS for_IN each_DT specimen_NN
          were_VBD obtained_VBN by_IN extrapolation_NN of_IN optical_JJ densities_NNS (_( OD_NNP )_)
          from_IN a_DT standard_JJ curve_NN derived_VBN from_IN six_CD points_NNS ._. For_IN Sm_NNP ,_,
          the_DT negative_JJ /_NN positive_JJ cutoff_NN value_NN was_VBD 10_CD IU_NNP /_NN ml_NN serum_NN or_CC
          OD_NNP =_SYM 0_CD ._. 52_CD ._. For_IN RNP_NNP ,_, the_DT negative_JJ /_NN positive_JJ cutoff_NN value_NN
          was_VBD 5_CD IU_NNP /_NN ml_NN serum_NN or_CC OD_NNP =_SYM 0_CD ._. 32_CD ._.
        
        
          Detection_NNP of_IN antibodies_NNS to_TO U_NNP 1_CD -_: 70_CD kD_NN
          To_TO detect_VB the_DT presence_NN of_IN IgG_NNP antibodies_NNS to_TO the_DT U_NNP 1_CD -_: 70_CD
          kD_NN ribonuclear_NN protein_NN ,_, both_DT immunoblotting_VBG and_CC EIA_NNP
          methods_NNS were_VBD used_VBN as_IN described_VBN previously_RB [_NN 16_CD 17_CD 18_CD ]_NN ._.
          Each_DT sample_NN was_VBD tested_VBN by_IN immunoblot_NN against_IN Jurkat_NNP cell_NN
          lysates_NNS with_IN a_DT 1_CD :_: 100_CD dilution_NN of_IN sera_NN ,_, and_CC by_IN EIA_NNP against_IN
          a_DT bacterially_RB produced_VBN U_NNP 1_CD -_: 70_CD kD_NN fusion_NN protein_NN that_WDT
          comprised_VBN residues_NNS 1_CD -_: 205_CD of_IN u_NN 1_CD -_: 70_CD kD_NN ._. All_DT EIA_NNP assays_NNS were_VBD
          performed_VBN using_VBG a_DT serum_NN dilution_NN of_IN 1_CD :_: 1000_CD and_CC were_VBD run_VBN
          taking_VBG the_DT average_JJ OD_NNP of_IN duplicate_VB wells_NNS ._. EIA_NNP results_NNS
          were_VBD repeated_VBN for_IN any_DT samples_NNS where_WRB the_DT OD_NNP of_IN the_DT
          duplicate_VB wells_NNS varied_VBN by_IN more_JJR than_IN 0_CD ._. 05_CD ,_, and_CC for_IN all_DT
          samples_NNS with_IN positive_JJ results_NNS by_IN either_DT EIA_NNP or_CC
          immunoblot_NN ._. In_IN cases_NNS where_WRB discrepant_NN results_NNS were_VBD
          obtained_VBN between_IN immunoblot_NN and_CC EIA_NNP testing_NN ,_, sera_NN were_VBD
          immunoblotted_JJ using_VBG a_DT more_RBR sensitive_JJ technique_NN against_IN
          both_DT intact_JJ and_CC apoptotic_JJ Jurkat_NNP lysates_NNS ,_, as_RB previously_RB
          described_VBD [_NN 18_CD 19_CD ]_NN using_VBG sera_NN diluted_VBD 1_CD :_: 5000_CD ._.
          Negative_JJ immunoblot_NN and_CC EIA_NNP results_NNS demonstrated_VBD the_DT
          absence_NN of_IN significant_JJ titers_NNS of_IN IgG_NNP antibodies_NNS to_TO U_NNP 1_CD -_: 70_CD
          kD_NN ._. Positive_JJ results_NNS on_IN immunoblot_NN and_CC EIA_NNP or_CC a_DT positive_JJ
          result_NN on_IN one_CD of_IN these_DT two_CD tests_NNS and_CC a_DT positive_JJ
          immunoblot_NN for_IN apoptotic_JJ U_NNP 1_CD -_: 70_CD kD_NN demonstrated_VBD the_DT
          presence_NN of_IN antibodies_NNS to_TO U_NNP 1_CD -_: 70_CD kD_NN ._. A_DT positive_JJ immunoblot_NN
          result_NN that_WDT was_VBD not_RB confirmed_VBN by_IN EIA_NNP or_CC follow-up_JJ
          immunoblot_NN would_MD probably_RB reflect_VB recognition_NN of_IN an_DT
          antigen_NN other_JJ than_IN U_NNP 1_CD -_: 70_CD kD_NN with_IN similar_JJ electrophoretic_JJ
          motility_NN (_( i_NNP ._. e_SYM ._. a_DT negative_JJ result_NN )_) ._. An_DT isolated_VBN positive_JJ
          EIA_NNP was_VBD an_DT indeterminate_JJ finding_NN ;_: the_DT weaker_JJR the_DT
          recognition_NN ,_, the_DT less_RBR likely_JJ it_PRP was_VBD to_TO be_VB valid_JJ ._. A_DT
          positive_JJ EIA_NNP result_NN was_VBD an_DT OD_NNP value_NN above_IN 0_CD ._. 100_CD ._. If_IN
          either_DT the_DT EIA_NNP or_CC the_DT immunoblot_NN produced_VBD positive_JJ
          results_NNS ,_, the_DT more_RBR sensitive_JJ apoptotic_JJ assay_NN was_VBD used_VBN to_TO
          verify_VB the_DT presence_NN of_IN antibodies_NNS to_TO U_NNP 1_CD -_: 70_CD kD_NN ._. The_DT
          sensitivity_NN of_IN these_DT assays_NNS has_VBZ been_VBN previously_RB
          established_VBN [_NN 16_CD 17_CD 18_CD 19_CD ]_NN ._.
        
        
          Detection_NNP of_IN antibodies_NNS to_TO gB_NN
          Quantitative_NNP levels_NNS of_IN antibodies_NNS against_IN CMV_NNP gB_NN were_VBD
          measured_VBN by_IN EIA_NNP in_IN all_DT seropositive_JJ sera_NN as_RB previously_RB
          described_VBD [_NN 20_CD ]_NN ._. The_DT OD_NNP value_NN obtained_VBN for_IN the_DT 1_CD :_: 1600_CD
          dilution_NN for_IN each_DT serum_NN was_VBD used_VBN for_IN statistical_JJ
          calculations_NNS ._. The_DT gB_NN antigen_NN used_VBN in_IN this_DT assay_NN was_VBD a_DT
          recombinant_JJ derivative_NN of_IN human_JJ CMV_NNP strain_NN Towne_NNP gB_NN
          produced_VBN as_IN a_DT secreted_JJ protein_NN in_IN Chinese_JJ hamster_NN ovary_JJ
          cells_NNS [_NN 21_CD ]_NN ._. The_DT recombinant_JJ gB_NN includes_VBZ amino_JJ acids_NNS
          1_CD -_: 676_CD of_IN the_DT extracellular_NN domain_NN ._. The_DT proteolytic_JJ
          cleavage_NN site_NN at_IN amino_JJ acid_NN 437_CD was_VBD blocked_VBN by_IN the_DT
          site-specific_JJ mutation_NN of_IN amino_JJ acid_NN residues_NNS 433_CD ,_, 434_CD ,_,
          and_CC 436_CD [_NN 22_CD ]_NN ._.
        
        
          Statistical_NNP calculations_NNS
          Comparisons_NNP were_VBD carried_VBN out_IN using_VBG Student_NNP 's_POS 
          t_NN test_NN or_CC chi-square_JJ analysis_NN ._.
          Regression_NNP analysis_NN was_VBD performed_VBN using_VBG Sigma_NNP Plot_NNP
          (_( version_NN 1_CD ._. 02_CD ;_: Jandel_NNP Corporation_NNP ,_, San_NNP Rafael_NNP ,_, CA_NNP ,_,
          USA_NNP )_) ._.
        
      
      
        Results_NNS
        
          Antibodies_NNP against_IN Sm_NNP and_CC RNP_NNP
          Using_VBG the_DT manufacturer_NN 's_POS sera_NN to_TO establish_VB a_DT
          negative_JJ /_NN positive_JJ cutoff_NN value_NN ,_, none_NN of_IN the_DT sera_NN tested_VBN
          contained_VBD detectable_JJ levels_NNS of_IN antibodies_NNS to_TO either_CC Sm_NNP or_CC
          RNP_NNP (_( Table_NNP 1_LS )_) ._. For_IN Sm_NNP ,_, using_VBG the_DT mean_NN OD_NNP plus_CC two_CD
          standard_JJ deviations_NNS (_( Table_NNP 1_LS )_) of_IN the_DT 40_CD CMV_NNP seronegative_JJ
          sera_NN to_TO establish_VB a_DT negative_JJ /_NN positive_JJ cutoff_NN value_NN ,_, none_NN
          of_IN the_DT 40_CD CMV_NNP seropositive_JJ sera_NN were_VBD positive_JJ ,_, one_CD of_IN the_DT
          CMV_NNP seronegative_JJ sera_NN was_VBD positive_JJ (_( OD_NNP =_SYM 0_CD ._. 422_CD )_) ,_, and_CC none_NN
          of_IN the_DT sera_NN from_IN the_DT vaccine_NN recipients_NNS were_VBD positive_JJ ._.
          For_IN RNP_NNP ,_, using_VBG the_DT mean_NN OD_NNP plus_CC two_CD standard_JJ deviations_NNS
          (_( Table_NNP 1_LS )_) of_IN the_DT 40_CD CMV_NNP seronegative_JJ sera_NN to_TO establish_VB a_DT
          negative_JJ /_NN positive_JJ cutoff_NN value_NN ,_, two_CD of_IN the_DT 40_CD CMV_NNP
          seronegative_JJ sera_NN were_VBD positive_JJ (_( OD_NNP =_SYM 0_CD ._. 22_CD and_CC 0_CD ._. 30_CD )_) ,_,
          three_CD of_IN the_DT CMV_NNP seropositive_JJ sera_NN were_VBD positive_JJ (_( OD_NNP =_SYM
          0_CD ._. 25_CD ,_, 0_CD ._. 26_CD and_CC 0_CD ._. 25_CD )_) ,_, and_CC none_NN of_IN the_DT sera_NN from_IN the_DT
          vaccine_NN recipients_NNS were_VBD positive_JJ ._.
          To_TO determine_VB whether_IN there_EX was_VBD a_DT statistically_RB
          significant_JJ association_NN between_IN levels_NNS of_IN antibodies_NNS to_TO
          CMV_NNP gB_NN and_CC the_DT levels_NNS of_IN antibodies_NNS to_TO Sm_NNP antigen_NN or_CC RNP_NNP
          antigen_NN ,_, a_DT simple_JJ linear_JJ regression_NN analysis_NN of_IN gB_NN OD_NNP
          values_NNS versus_CC Sm_NNP and_CC RNP_NNP OD_NNP values_NNS for_IN sera_NN from_IN CMV_NNP
          seropositive_JJ subjects_NNS and_CC for_IN sera_NN from_IN vaccines_NNS at_IN 4_CD and_CC
          12_CD months_NNS after_IN immunization_NN was_VBD performed_VBN ._. No_DT
          significant_JJ correlations_NNS were_VBD found_VBN (_( Table_NNP 2_LS )_) ._.
        
        
          Antibodies_NNP against_IN U_NNP 1_CD -_: 70_CD kD_NN
          Using_VBG the_DT EIA_NNP with_IN U_NNP 1_CD -_: 70_CD kD_NN as_IN the_DT antigen_NN ,_, only_RB one_CD
          of_IN 104_CD sera_NN tested_VBN was_VBD positive_JJ (_( OD_NNP =_SYM 0_CD ._. 121_CD )_) ._. That_DT one_CD
          serum_NN was_VBD negative_JJ using_VBG an_DT immunoblot_NN with_IN apoptotic_JJ
          Jurkat_NNP cells_NNS ._. Using_VBG an_DT immunoblot_NN ,_, three_CD of_IN 104_CD sera_NN were_VBD
          positive_JJ and_CC three_CD sera_NN were_VBD weakly_RB positive_JJ ._. None_NN of_IN the_DT
          three_CD weakly_RB positive_JJ sera_NN were_VBD positive_JJ using_VBG an_DT
          immunoblot_NN with_IN apoptotic_JJ Jurkat_NNP cells_NNS ,_, but_CC two_CD of_IN the_DT
          three_CD sera_NN positive_JJ by_IN immunoblot_NN were_VBD also_RB positive_JJ
          using_VBG an_DT immunoblot_NN with_IN apoptotic_JJ Jurkat_NNP cells_NNS ._. No_DT sera_NN
          was_VBD positive_JJ both_DT by_IN immunoblot_NN and_CC by_IN EIA_NNP ._. There_EX was_VBD no_DT
          significant_JJ difference_NN for_IN the_DT rate_NN of_IN positivity_NN between_IN
          sera_NN obtained_VBN for_IN CMV_NNP seropositive_JJ subjects_NNS and_CC CMV_NNP
          seronegative_JJ subjects_NNS (_( Table_NNP 3_LS )_) ._. None_NN of_IN the_DT recipients_NNS
          of_IN CMV_NNP vaccine_NN developed_VBD antibodies_NNS to_TO U_NNP 1_CD -_: 70_CD kD_NN (_( Table_NNP
          3_LS )_) ._.
        
      
      
        Discussion_NNP
        The_DT present_JJ study_NN was_VBD designed_VBN to_TO confirm_VB the_DT report_NN of_IN
        Newkirk_NNP 
        et_CC al_NN ._. They_PRP reported_VBD that_IN ,_, among_IN the_DT
        sera_NN of_IN 100_CD normal_JJ healthy_JJ adults_NNS (_( 50_CD CMV_NNP seropositive_JJ and_CC
        50_CD CMV_NNP seronegative_JJ )_) ,_, 54_CD %_NN contained_VBD antibodies_NNS to_TO RNP_NNP ,_, 50_CD %_NN
        contained_VBD antibodies_NNS to_TO Sm_NNP ,_, and_CC 33_CD %_NN contained_VBD antibodies_NNS to_TO
        U_NNP 1_CD -_: 70_CD kD_NN [_NN 14_CD ]_NN ._.
        Newkirk_NNP 
        et_CC al_NN ._. also_RB observed_VBD that_IN the_DT
        frequency_NN of_IN autoantibodies_NNS to_TO each_DT of_IN the_DT antigens_NNS
        occurred_VBD more_RBR frequently_RB among_IN CMV_NNP seropositive_JJ subjects_NNS
        than_IN among_IN CMV_NNP seronegative_JJ subjects_NNS [_NN 14_CD ]_NN ._. For_IN CMV_NNP
        seropositive_JJ subjects_NNS ,_, they_PRP observed_VBD that_IN 42_CD (_( 84_CD %_NN )_) subjects_NNS
        had_VBD antibodies_NNS to_TO RNP_NNP ,_, 32_CD (_( 64_CD %_NN )_) had_VBD antibodies_NNS to_TO Sm_NNP ,_, and_CC
        23_CD (_( 46_CD %_NN )_) had_VBD antibodies_NNS to_TO U_NNP 1_CD -_: 70_CD kD_NN [_NN 14_CD ]_NN ._. If_IN Newkirk_NNP 
        et_CC al_NN ._. used_VBD a_DT negative_JJ /_NN positive_JJ
        cutoff_NN value_NN of_IN the_DT mean_NN plus_CC three_CD standard_JJ deviations_NNS
        then_RB ,_, overall_JJ ,_, less_JJR than_IN 10_CD %_NN of_IN their_PRP$ sera_NN contained_VBD
        autoantibodies_NNS ._.
        We_PRP could_MD not_RB reproduce_VB the_DT data_NNS of_IN Newkirk_NNP 
        et_CC al_NN ._. The_DT subjects_NNS in_IN the_DT study_NN of_IN
        Newkirk_NNP 
        et_CC al_NN ._. were_VBD similar_JJ to_TO our_PRP$ subjects_NNS ;_:
        80_CD %_NN female_JJ and_CC 98_CD %_NN Caucasian_NNP ._. Although_IN there_EX are_VBP only_RB a_DT few_JJ
        published_VBN reports_NNS on_IN the_DT frequency_NN of_IN these_DT antibodies_NNS in_IN
        normal_JJ populations_NNS ,_, those_DT published_VBN reports_NNS all_DT find_VBP a_DT
        frequency_NN of_IN between_IN 0_CD and_CC 3_CD %_NN ,_, similar_JJ to_TO those_DT reported_VBD in_IN
        the_DT present_JJ study_NN [_NN 23_CD 24_CD 25_CD 26_CD 27_CD ]_NN ._. One_CD study_NN of_IN over_IN
        1000_CD healthy_JJ pregnant_JJ and_CC nonpregnant_NN Israeli_JJ women_NNS found_VBD
        that_DT none_NN had_VBD IgG_NNP antibodies_NNS to_TO either_CC Sm_NNP or_CC RNP_NNP ._. IgM_NNP
        antibodies_NNS ,_, however_RB ,_, were_VBD detected_VBN in_IN 4_CD %_NN or_CC less_JJR of_IN
        subjects_NNS ._. Patients_NNS with_IN autoimmune_JJ disease_NN have_VBP
        predominantly_RB IgG_NNP antibodies_NNS to_TO Sm_NNP and_CC to_TO RNP_NNP ,_, and_CC to_TO a_DT
        lesser_JJR extent_NN IgM_NNP antibodies_NNS ,_, whereas_IN patients_NNS with_IN
        inactive_JJ autoimmune_JJ disease_NN are_VBP most_RBS likely_JJ to_TO have_VB IgM_NNP
        antibodies_NNS to_TO these_DT antigens_NNS [_NN 28_CD 29_CD ]_NN ._. Both_DT the_DT present_JJ
        study_NN and_CC that_IN of_IN Newkirk_NNP 
        et_CC al_NN ._. measured_VBN IgG_NNP antibodies_NNS to_TO
        these_DT nuclear_JJ antigens_NNS ._.
        Several_JJ factors_NNS may_MD account_VB for_IN the_DT difference_NN between_IN
        our_PRP$ results_NNS and_CC those_DT of_IN Newkirk_NNP 
        et_CC al_NN ._. Differences_NNS in_IN assay_NN methods_NNS
        or_CC antigens_NNS could_MD be_VB important_JJ ._. This_DT is_VBZ suggested_VBN by_IN the_DT
        fact_NN that_IN the_DT mean_NN OD_NNP (_( >_NN 0_CD ._. 5_LS )_) observed_VBN by_IN Newkirk_NNP 
        et_CC al_NN ._. in_IN their_PRP$ Sm_NNP and_CC RNP_NNP EIA_NNP
        assays_NNS was_VBD significantly_RB higher_JJR than_IN the_DT mean_NN OD_NNP (_( <_NN 0_CD ._. 15_CD )_)
        observed_VBD in_IN the_DT present_JJ study_NN ._. Another_DT possibility_NN relates_VBZ
        to_TO the_DT negative_JJ /_NN positive_JJ cutoff_NN value_NN used_VBN ._. For_IN all_DT three_CD
        antigens_NNS ,_, Newkirk_NNP 
        et_CC al_NN ._. used_VBN EIA_NNP assays_NNS and_CC
        established_VBD their_PRP$ negative_JJ /_NN positive_JJ cutoff_NN value_NN using_VBG the_DT
        mean_NN plus_CC two_CD standard_JJ deviations_NNS of_IN 15_CD CMV_NNP seronegative_JJ
        sera_NN [_NN 14_CD ]_NN ._. This_DT appears_VBZ to_TO have_VB resulted_VBN in_IN a_DT
        negative_JJ /_NN positive_JJ cutoff_NN value_NN significantly_RB lower_JJR than_IN
        that_DT observed_VBD in_IN the_DT present_JJ study_NN using_VBG either_CC the_DT
        manufacturer_NN 's_POS recommended_VBD cutoff_NN value_NN or_CC our_PRP$ own_JJ cutoff_NN
        value_NN established_VBN with_IN the_DT 40_CD seronegative_JJ sera_NN ._. To_TO detect_VB
        antibodies_NNS to_TO U_NNP 1_CD -_: 70_CD kD_NN ,_, Newkirk_NNP 
        et_CC al_NN ._. used_VBN only_RB an_DT EIA_NNP assay_NN ._. Using_VBG
        the_DT EIA_NNP assay_NN ,_, we_PRP found_VBD only_RB one_CD of_IN 104_CD sera_NN contained_VBD
        antibodies_NNS to_TO this_DT protein_NN ._.
        Another_DT factor_NN that_WDT may_MD account_VB for_IN the_DT difference_NN
        between_IN our_PRP$ results_NNS and_CC those_DT of_IN Newkirk_NNP 
        et_CC al_NN ._. is_VBZ the_DT prevalence_NN of_IN the_DT HLA_NNP
        antigen_NN DR_NNP 4_CD ._. This_DT HLA_NNP type_NN occurs_VBZ among_IN 60_CD %_NN of_IN patients_NNS
        with_IN autoimmune_JJ disease_NN and_CC antibodies_NNS to_TO U_NNP 1_CD -_: 70_CD kD_NN ,_, but_CC its_PRP$
        prevalence_NN in_IN the_DT normal_JJ healthy_JJ individuals_NNS is_VBZ only_RB about_IN
        25_CD %_NN [_NN 16_CD 30_CD ]_NN ._. Hence_RB ,_, if_IN the_DT association_NN between_IN HLA_NNP DR_NNP 4_CD
        and_CC the_DT presence_NN of_IN antibodies_NNS to_TO U_NNP 1_CD -_: 70_CD kD_NN exists_VBZ for_IN
        healthy_JJ individuals_NNS and_CC if_IN ,_, due_JJ to_TO selection_NN bias_NN ,_, our_PRP$
        population_NN contained_VBD very_RB few_JJ (_( <_NN 4_CD %_NN )_) DR_NNP 4_CD -_: positive_JJ
        individuals_NNS and_CC the_DT population_NN of_IN Newkirk_NNP 
        et_CC al_NN ._. contained_VBD a_DT very_RB high_JJ (_( ≥_NN 50_CD %_NN )_)
        prevalence_NN of_IN DR_NNP 4_CD -_: positive_JJ subjects_NNS ,_, this_DT could_MD account_VB for_IN
        the_DT observed_VBN differences_NNS ._. This_DT possibility_NN ,_, however_RB ,_, seems_VBZ
        very_RB improbable_JJ ._.
        In_IN another_DT study_NN ,_, Newkirk_NNP and_CC coworkers_NNS also_RB observed_VBD
        that_IN a_DT recombinant_JJ gB_NN vaccine_NN ,_, which_WDT expressed_VBD the_DT gB_NN
        protein_NN of_IN the_DT Towne_NNP vaccine_NN ,_, induced_VBN antibodies_NNS to_TO CMV_NNP gB_NN
        when_WRB administered_VBN to_TO mice_NNS ,_, suggesting_VBG that_IN CMV_NNP gB_NN induces_VBZ
        antibodies_NNS crossreactive_JJ to_TO U_NNP 1_CD -_: 70_CD kD_NN [_NN 13_CD ]_NN ._. If_IN this_DT is_VBZ
        the_DT case_NN ,_, it_PRP predicts_VBZ a_DT correlation_NN between_IN levels_NNS of_IN
        antibodies_NNS to_TO gB_NN and_CC U_NNP 1_CD -_: 70_CD kD_NN in_IN sera_NN ._. In_IN humans_NNS ,_, neither_DT
        the_DT present_JJ study_NN or_CC that_IN of_IN Newkirk_NNP and_CC colleagues_NNS [_NN 13_CD ]_NN
        found_VBD such_JJ a_DT correlation_NN ._. This_DT indicates_VBZ that_IN either_DT there_EX
        is_VBZ no_DT such_JJ crossreactivity_NN or_CC that_IN ,_, if_IN it_PRP exists_VBZ ,_, it_PRP occurs_VBZ
        very_RB infrequently_RB or_CC only_RB to_TO a_DT few_JJ epitopes_NNS ._. It_PRP is_VBZ also_RB
        possible_JJ that_IN the_DT mice_NNS Newkirk_NNP and_CC coworkers_NNS used_VBN were_VBD
        genetically_RB primed_VBN to_TO produce_VB autoantibodies_NNS in_IN response_NN to_TO
        this_DT antigen_NN ._.
        Whether_IN viruses_NNS cause_VBP autoimmune_JJ disease_NN is_VBZ
        controversial_JJ ._. If_IN they_PRP do_VBP cause_VB disease_NN ,_, several_JJ mechanisms_NNS
        may_MD explain_VB the_DT association_NN between_IN viruses_NNS and_CC autoimmune_JJ
        disease_NN ._. To_TO stimulate_VB a_DT complete_JJ autoimmune_JJ response_NN ,_, two_CD
        signals_NNS (_( one_CD antigen_NN specific_JJ and_CC one_CD not_RB antigen_NN
        specific_JJ )_) ,_, are_VBP necessary_JJ [_NN 31_CD ]_NN ._. The_DT best_JJS described_VBN
        antigen-specific_JJ mechanism_NN is_VBZ molecular_JJ mimicry_NN ,_, whereby_WRB
        some_DT component_NN of_IN the_DT offending_VBG virus_NN resembles_VBZ the_DT host_NN
        structure_NN on_IN a_DT molecular_JJ level_NN ,_, thus_RB providing_VBG the_DT template_NN
        for_IN antibody_NN formation_NN that_WDT may_MD crossreact_NN with_IN
        self-antigen_JJ ._. Several_JJ of_IN the_DT nonantigen-specific_JJ signals_NNS
        include_VBP costimulatory_NN cell_NN surface_NN markers_NNS as_RB well_RB as_IN the_DT
        generation_NN of_IN a_DT multitude_NN of_IN cytokines_NNS ._. Theoretically_RB ,_,
        viruses_NNS may_MD play_VB a_DT role_NN in_IN eliciting_VBG either_DT or_CC both_DT of_IN
        these_DT signals_NNS ._.
        Infection_NNP with_IN CMV_NNP is_VBZ ubiquitous_JJ within_IN the_DT human_JJ
        population_NN ,_, and_CC nearly_RB 100_CD %_NN of_IN humans_NNS eventually_RB acquire_VB a_DT
        CMV_NNP infection_NN ._. On_IN the_DT contrary_JJ ,_, autoimmune_JJ disease_NN is_VBZ
        relatively_RB rare_JJ ,_, occurring_VBG in_IN less_JJR than_IN 5_CD %_NN of_IN the_DT
        population_NN ._. If_IN CMV_NNP was_VBD a_DT frequent_JJ inducer_NN of_IN
        autoantibodies_NNS ,_, and_CC by_IN implication_NN an_DT autoimmune_JJ disease_NN ,_,
        both_DT the_DT frequency_NN of_IN autoantibodies_NNS in_IN disease-free_JJ
        individuals_NNS and_CC the_DT incidence_NN of_IN autoimmune_JJ disease_NN in_IN the_DT
        general_JJ population_NN would_MD be_VB much_RB higher_RBR than_IN observed_VBN by_IN
        other_JJ workers_NNS and_CC ourselves_PRP ._. It_PRP is_VBZ not_RB excluded_VBN ,_, however_RB ,_,
        that_IN a_DT low_JJ frequency_NN of_IN these_DT three_CD autoantibodies_NNS may_MD be_VB
        infrequently_RB but_CC significantly_RB associated_VBN with_IN CMV_NNP
        infection_NN ._. To_TO establish_VB this_DT will_MD require_VB testing_VBG of_IN a_DT
        large_JJ number_NN of_IN sera_NN ._. For_IN example_NN ,_, testing_NN of_IN nearly_RB 700_CD
        sera_NN will_MD be_VB required_VBN to_TO determine_VB whether_IN an_DT autoantibody_NN
        frequency_NN of_IN 5_CD %_NN among_IN CMV_NNP seropositive_JJ individuals_NNS and_CC of_IN
        1_CD %_NN among_IN CMV_NNP seronegative_JJ individuals_NNS is_VBZ a_DT significant_JJ
        difference_NN ._.
      
      
        Conclusion_NNP
        We_PRP failed_VBD to_TO detect_VB antibodies_NNS to_TO either_CC Sm_NNP or_CC RNP_NNP in_IN
        individuals_NNS infected_VBN with_IN wild-type_JJ CMV_NNP or_CC in_IN eight_CD
        individuals_NNS vaccinated_JJ with_IN the_DT Towne_NNP strain_NN of_IN CMV_NNP ._.
        Likewise_RB ,_, regression_NN analysis_NN of_IN levels_NNS of_IN antibodies_NNS to_TO
        CMV_NNP gB_NN ,_, the_DT major_JJ antibody_NN formed_VBN after_IN natural_JJ infection_NN
        or_CC active_JJ immunization_NN ,_, failed_VBD to_TO demonstrate_VB a_DT correlation_NN
        with_IN the_DT levels_NNS of_IN antibodies_NNS to_TO Sm_NNP and_CC to_TO RNP_NNP ._. With_IN
        regards_VBZ to_TO antibody_NN to_TO U_NNP 1_CD -_: 70_CD kD_NN ,_, which_WDT may_MD be_VB a_DT more_RBR
        sensitive_JJ indicator_NN of_IN autoimmune_JJ disease_NN ,_, the_DT sera_NN from_IN
        only_RB one_CD CMV_NNP seropositive_JJ subject_NN contained_VBD these_DT
        antibodies_NNS and_CC none_NN of_IN the_DT sera_NN of_IN the_DT vaccinees_NNS contained_VBD
        these_DT antibodies_NNS ._. These_DT results_NNS indicate_VBP that_IN CMV_NNP infection_NN
        induces_VBZ these_DT autoantibodies_NNS infrequently_RB and_CC that_IN
        autoimmune_JJ disease_NN associated_VBN with_IN CMV_NNP infection_NN is_VBZ
        probably_RB rare_JJ ._.
      
      
        Abbreviations_NNP
        CMV_NNP =_SYM cytomegalovirus_JJ ;_: EIA_NNP =_SYM enzyme_NN immunoassay_NN ;_: gB_NN =_SYM
        glycoprotein_NN B_NNP ;_: OD_NNP =_SYM optical_JJ density_NN ;_: RNP_NNP =_SYM
        ribonucleoprotein_NN ;_: Sm_NNP =_SYM ribonucleoproteins_NNS recognized_VBN by_IN
        antibodies_NNS from_IN a_DT patient_NN named_VBD Smith_NNP ;_: U_NNP 1_CD -_: 70_CD kD_NN =_SYM component_NN
        of_IN the_DT U_NNP 1_CD ribonucleoproteins_NNS ._.
      
    
  
